Deciphera Pharmaceuticals Inc (DCPH) CFO Sells $125,900.00 in Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 5,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $25.18, for a total transaction of $125,900.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

NASDAQ DCPH opened at $25.89 on Friday. The company has a current ratio of 18.46, a quick ratio of 18.46 and a debt-to-equity ratio of 0.06. The stock has a market cap of $956.97 million, a price-to-earnings ratio of -8.66 and a beta of 3.38. Deciphera Pharmaceuticals Inc has a one year low of $18.55 and a one year high of $45.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, meeting analysts’ consensus estimates of ($0.65). On average, equities research analysts expect that Deciphera Pharmaceuticals Inc will post -2.62 EPS for the current year.



A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC increased its position in Deciphera Pharmaceuticals by 14.1% during the 3rd quarter. Teachers Advisors LLC now owns 17,187 shares of the company’s stock valued at $665,000 after purchasing an additional 2,119 shares during the period. Legal & General Group Plc grew its position in shares of Deciphera Pharmaceuticals by 55.4% in the 3rd quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after buying an additional 587 shares during the last quarter. Vanguard Group Inc grew its position in shares of Deciphera Pharmaceuticals by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 675,517 shares of the company’s stock worth $26,156,000 after buying an additional 14,081 shares during the last quarter. Federated Investors Inc. PA purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter worth approximately $1,113,000. Finally, Vanguard Group Inc. grew its position in shares of Deciphera Pharmaceuticals by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 675,517 shares of the company’s stock worth $26,156,000 after buying an additional 14,081 shares during the last quarter. 55.04% of the stock is currently owned by institutional investors and hedge funds.

DCPH has been the subject of a number of research analyst reports. Guggenheim initiated coverage on shares of Deciphera Pharmaceuticals in a report on Monday, September 17th. They set a “buy” rating for the company. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Tuesday, October 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $53.00 price objective on shares of Deciphera Pharmaceuticals in a report on Wednesday, October 3rd. ValuEngine upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Finally, B. Riley initiated coverage on shares of Deciphera Pharmaceuticals in a report on Monday, December 31st. They set a “buy” rating and a $34.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. Deciphera Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $42.67.

COPYRIGHT VIOLATION NOTICE: “Deciphera Pharmaceuticals Inc (DCPH) CFO Sells $125,900.00 in Stock” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/01/11/deciphera-pharmaceuticals-inc-dcph-cfo-sells-125900-00-in-stock.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Further Reading: What are the components of an earnings report?

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply